What’s New in Bioanalysis?

LNP Analytics

Beyond Particle Size: Building a Complete Analytical Strategy for LNPs

Pharma's Almanac

API Oversight

Can Regulatory Reliance Make Global API Oversight More Efficient?

Pharma's Almanac

NAMs

The EMA Builds a Regulatory Safe Harbor for New Approach Methodologies

Pharma's Almanac

Oncolytic Viruses

Turning Oncolytic Viruses into Manufacturable Cancer Therapies

Luisa Amoedo Otero

Recipharm Advanced Bio

Drug Shortage

What It Actually Takes to Engineer a Drug Supply Chain Out of Shortage

David Alvaro, Ph.D.

Pharma's Almanac

CCS and CMC

Packaging Returns to the Center of CMC Strategy

Pharma's Almanac

iPSCs

For iPSC Therapies, Manufacturing Consistency May Mean Preserving Function

Pharma's Almanac

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Preparedness

Preparing Manufacturing Networks for the Next Pandemic

Pharma's Almanac